Cardiovascular Outcomes: Wegovy vs Trulicity in Clinical Trials

When clinicians prescribe a GLP‑1 receptor agonist, the decision often hinges on more than just weight‑loss potential. For patients with type 2 diabetes or obesity, the impact on cardiovascular health is a critical factor. This article reviews the most recent clinical trials that evaluated cardiovascular events for two leading agents—Wegovy (semaglutide) and Trulicity (dulaglutide). By summarizing the evidence, we aim to help you make an informed, heart‑healthy choice.

Understanding GLP‑1 Receptor Agonists

GLP‑1 (glucagon‑like peptide‑1) receptor agonists mimic the incretin hormone GLP‑1, enhancing insulin secretion, slowing gastric emptying, and reducing appetite. While originally developed for glycemic control, several agents have demonstrated cardiovascular benefits, prompting FDA‑mandated outcome trials. The most widely discussed drugs in this class include Ozempic, Wegovy, Mounjaro, and Zepbound. Both Wegovy and Trulicity belong to this family, but they differ in molecular structure, dosing schedule, and the specific patient populations studied in their pivotal trials.

Wegovy (Semaglutide) Cardiovascular Data

The primary cardiovascular evidence for semaglutide comes from the STEP (Semaglutide Treatment Effect in People with Obesity) program and the SUSTAIN‑6 trial, which evaluated the same molecule at a lower dose under the brand name Ozempic. Although STEP focused on weight‑loss outcomes, it also tracked major adverse cardiovascular events (MACE), defined as cardiovascular death, non‑fatal myocardial infarction, or non‑fatal stroke.

In these studies, researchers reported an approximate 15‑20 % relative risk reduction for MACE compared with placebo. The benefit appeared consistent across subgroups, including patients with established atherosclerotic cardiovascular disease and those at high risk but without prior events. Because the trials used a once‑weekly injection, adherence was generally high, and the safety profile was favorable, with gastrointestinal side effects being the most common adverse events.

Trulicity (Dulaglutide) Cardiovascular Data

Trulicity’s cardiovascular evidence is anchored in the REWIND (Research on Cardiovascular Disease in Patients with Diabetes) trial, which enrolled over 9,000 adults with type 2 diabetes, many of whom had a prior cardiovascular event. Over a median follow‑up of nearly six years, dulaglutide demonstrated an approximate 12 % relative risk reduction in MACE versus placebo.

The REWIND population was broader than that of SUSTAIN‑6, incorporating patients with lower baseline cardiovascular risk. This design provides insight into the drug’s potential benefit for primary prevention. As with Wegovy, the most frequently reported side effects were gastrointestinal, but they were typically mild to moderate and transient.

Direct Comparison: What Do the Data Tell Us?

When placing Wegovy and Trulicity side by side, several themes emerge:

Magnitude of benefit: Both agents reduce the risk of major cardiovascular events, with Wegovy showing a slightly larger relative reduction (≈15‑20 % vs. ≈12 %). However, the difference is modest and may reflect variations in trial design rather than true superiority.
Patient populations: Wegovy’s pivotal trials focused on individuals with obesity (BMI ≥ 30 kg/m²) and often included patients with established cardiovascular disease. Trulicity’s REWIND trial captured a broader diabetes cohort, including many without prior events, suggesting a possible primary‑prevention advantage.
Duration of follow‑up: REWIND followed participants for a longer period (≈6 years) compared with the median 2‑year follow‑up of the STEP trials. Longer exposure may offer a more realistic view of long‑term safety and efficacy.
Dosing convenience: Both drugs are administered once weekly, but the injection devices differ. Some patients prefer the pre‑filled pen of Trulicity, while others find the smaller needle of Wegovy’s pen easier to use.

Overall, the evidence suggests that either medication can be part of a heart‑healthy strategy, with the final choice often guided by individual risk factors, weight‑loss goals, and personal preferences.

Considerations Beyond Cardiovascular Outcomes

While cardiovascular risk reduction is a key driver, clinicians and patients also weigh other factors:

Weight‑loss efficacy: Wegovy has demonstrated robust weight loss—often exceeding 15 % of baseline body weight in the STEP trials—making it attractive for obesity management. Trulicity’s weight‑loss effects are modest but still clinically meaningful.
Glycemic control: For patients with type 2 diabetes, both agents lower HbA1c, with dulaglutide showing a slightly larger average reduction in the REWIND cohort.
Side‑effect profile: Nausea, vomiting, and diarrhea are the most common adverse events for both drugs. However, the incidence tends to be higher with Wegovy due to its higher dose used for weight loss.
Cost and insurance coverage: Pricing varies by formulation and region. Some insurers may favor one agent over the other based on formulary placement, prior‑authorization requirements, or patient assistance programs.
Convenience and adherence: Both medications are once‑weekly injections, but the pen design and needle size differ. Patient education on proper injection technique can improve adherence and reduce injection‑site reactions.

Frequently Asked Questions

Is the cardiovascular benefit of Wegovy proven for patients without obesity?

The primary cardiovascular data for semaglutide come from studies that enrolled participants with obesity or overweight. However, the SUSTAIN‑6 trial, which used a lower dose of semaglutide (Ozempic) in patients with type 2 diabetes, also demonstrated a meaningful reduction in MACE. This suggests that the cardiovascular benefit extends to individuals without severe obesity, especially those with diabetes.

Can Trulicity be used for weight loss?

Trulicity is FDA‑approved for glycemic control in type 2 diabetes, not for obesity management. Nonetheless, many patients experience modest weight loss as a secondary effect. If weight loss is a primary goal, clinicians often consider Wegovy or other GLP‑1 agents with stronger evidence for weight reduction.

Do the cardiovascular benefits persist after stopping the medication?

Current evidence indicates that the cardiovascular advantage is linked to ongoing treatment. Discontinuation of a GLP‑1 agonist typically leads to a gradual return of baseline risk levels. Therefore, sustained therapy is recommended for patients who derive cardiovascular benefit.

Are there any head‑to‑head trials directly comparing Wegovy and Trulicity?

As of now, no large‑scale, direct comparative trial has been published that pits Wegovy against Trulicity. Most conclusions are drawn from separate, well‑designed studies. Future head‑to‑head research could clarify any nuanced differences in efficacy, safety, and cardiovascular outcomes.

Getting Started with GLP‑1

If you are considering a GLP‑1 receptor agonist to improve your cardiovascular health, the first step is to determine whether you meet the clinical criteria. Eligibility typically includes a diagnosis of type 2 diabetes or obesity, along with a cardiovascular risk profile that aligns with the drug’s approved indication. Many patients find it convenient to begin the evaluation process through a licensed online provider, which can streamline the initial consultation, lab work, and prescription delivery.

To explore your options and see if you qualify for a GLP‑1 therapy, check your eligibility here. A qualified healthcare professional will review your medical history, discuss potential benefits and risks, and help you choose the therapy that best matches your health goals.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. The outcomes described are based on general clinical trial data and may not reflect individual results.